Cilcare is a biotech dedicated to harnessing auditory sciences to reshape the future of care via early diagnosis and targeted treatment. They believe hearing acts as a valuable indicator of our health and must be monitored and preserved accordingly. As awareness of the link between hearing and chronic health conditions grows, auditory sciences are paving the way for the early detection of chronic neurocognitive, inflammatory, and age-related diseases.

Founded in 2014 by three women with extensive backgrounds in the pharmaceutical industry, Cilcare initially aimed to address the significant unmet medical needs in ear diseases. Its approach focuses on translational research, supported by a cutting-edge R&D platform with robust pharmacological models. Partnering with CBSET, a translational institute linked to the MIT in 2017, Cilcare accelerated its mission, to drive transformative breakthroughs. Developing its own assets coupled with a unique AI-driven approach, Cilcare focuses on cochlear synaptopathy treatment and associated neuro-inflammatory disorders.

Cilcare stands out with a revolutionary strategy that merges drug development with state-of-the-art AI-driven approach, specifically tailored for auditory data analysis. Cilcare’s lead compound, CIL001, is ready to enter phase IIA in the treatment of cochlear synaptopathy, a hot topic in the scientific community, and affecting 15% of the population. Addressing an underexplored therapeutic domain, with a unique pharmacological pathway, position Cilcare and its lead compound at the forefront of innovation in the field of auditory sciences.

–  Therapeutic areas: Hearing disorders, Deafness, Tinnitus, Cochlear Synaptopathy, Otology, Auditory health and associated neuro-inflammatory diseases

–  Based in: Headquarter and Labs : Montpellier (FRANCE) Office : Paris (FRANCE) Office and Labs : Boston (US)

–  Employees: 11 – 50

–  Created in: 2014